| Name | CC-671 |
| Description | CC-671 is a dual inhibitor of TTK protein kinase (IC50: 0.005 μM) and CLK2 (IC50: 0.006 μM). |
| Kinase Assay | The kinase selectivity profile of CC-671 is assessed. The screen is conducted with the concentration of CC-671 held constant at 3 μM. The TTK binding affinity is measured using the kinase binding assays. The kinase binding assays are based on the binding and displacement of a proprietary, Alexa Fluor 647-labeled, ATP-competitive kinase inhibitor scaffold[1]. |
| Animal Research | Female SCID mice are inoculated subcutaneously with 5×106 Cal-51 cells. Mice with tumours of approximately 125 mm3 are randomized and treated intravenously at various doses and schedules of CC-671 (n=8 to10/group). Tumours are measured twice a week for the duration of the study. The long and short axes of each a tumour are measured using a digital calliper in millimetres and the tumour volumes are calculated[1]. |
| In vitro | HCT-116 cell lysates treated with CC-671 at 3 μM for 1 h demonstrates that only four kinases show cellular binding of 75% or more including CLK2, CAMKK2, PIP4K22, and JNK[1]. |
| In vivo | CC-671 significantly inhibits tumor growth by 71% at doses of both 10 and 20 mg/kg on an every 3 days (q3d) dosing schedule, with no difference in efficacy between the two doses. However, it induces greater body weight loss at 20 mg/kg compared to 10 mg/kg (17% vs 5%)[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (97.55 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.9 mM), Sonication is recommended.
|
| Keywords | TTK | Inhibitor | inhibit | Cyclin dependent kinase | CLK2 | CDK | CC-671 | CC671 | CC 671 |
| Inhibitors Related | Amantadine | 2-Chloropyrazine | Kojic acid | Ruxolitinib | Abemaciclib | Ibrutinib | Vidarabine | Palbociclib | Abemaciclib methanesulfonate | Gefitinib | Sodium Oxamate | Dinaciclib |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Preclinical Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
